Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1991-1-24
|
pubmed:abstractText |
Steady-state plasma levels of ketamine and its metabolites norketamine and dehydronorketamine were determined in 4 different groups of a total of 27 patients with ketamine long-term analgosedation (1.1 - 1.3 mg/kg/h). In 9 of the patients who had normal liver and kidney function (group 1), steady-state levels after 3 days of continuous infusion were 1.2 +/- 0.3 micrograms/ml ketamine, 1.0 +/- 0.6 micrograms/ml norketamine, and 2.6 +/- 1.0 micrograms/ml dehydronorketamine. The measured ketamine levels in group 1 were in agreement with the expected value, which may be calculated from published pharmacokinetic data after bolus injection. In 8 patients with acute renal failure (group 2), a tendency to about 20% higher ketamine steady-state plasma levels compared to group 1 was observed, but this difference was not significant. However, dehydronorketamine plasma levels were significantly higher in this group. Only a minor fraction of the ketamine dose (10% and 4%) was eliminated during hemodialysis or hemofiltration treatment, respectively. Steady-state plasma levels in 5 patients with cardiogenic shock (group 3) did not differ significantly from those of group 1. In 5 patients with long-term use of barbiturates (group 4), steady-state plasma levels of ketamine were significantly lower compared to groups 1 and 3, most likely due to barbiturate-induced enzyme induction. Hyperdynamic circulatory reactions were not observed in any of the patients. Psychomimetic effects could be excluded in 16 of the patients and were unlikely in 6 patients. In 5 further patients, psychomimetic effects could not definitely be excluded due to difficulties in non-verbal communication.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0378-7966
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
15
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
259-63
|
pubmed:dateRevised |
2011-2-2
|
pubmed:meshHeading |
pubmed-meshheading:2253657-Adult,
pubmed-meshheading:2253657-Aged,
pubmed-meshheading:2253657-Analgesics,
pubmed-meshheading:2253657-Enzyme Induction,
pubmed-meshheading:2253657-Female,
pubmed-meshheading:2253657-Heart,
pubmed-meshheading:2253657-Humans,
pubmed-meshheading:2253657-Hypnotics and Sedatives,
pubmed-meshheading:2253657-Ketamine,
pubmed-meshheading:2253657-Kidney,
pubmed-meshheading:2253657-Liver,
pubmed-meshheading:2253657-Male,
pubmed-meshheading:2253657-Middle Aged,
pubmed-meshheading:2253657-Time Factors
|
pubmed:articleTitle |
Effects of enzyme induction, renal and cardiac function on ketamine plasma kinetics in patients with ketamine long-term analgosedation.
|
pubmed:affiliation |
Reanimationszentrum, Universitätsklinikum Rudolf Virchow, Freie Universität Berlin, Germany.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|